August 22, 2025CancersOpen Access

UK Real-World Evidence of Using Durvalumab Plus Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer via an Early Access Scheme

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis shows comparable outcomes in biliary tract cancer patients, indicating a viable first-line treatment option.

Progression-free survival was 8.83 months, closely aligning with the 7.2 months noted in the TOPAZ-1 trial.
Overall survival reached 12 months, slightly lower than the 12.8 months reported in TOPAZ-1, suggesting similar effectiveness.
Safety outcomes revealed that 52.3% of patients experienced adverse events, indicating a favorable toxicity profile.
Overall response rate was 29.1%, slightly exceeding the 26.7% reported in the TOPAZ-1 trial, affirming treatment efficacy.

Daniels et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark